MPS Pharmaa Ltd (531686) — FY26 Annual Report | 5 September 2026 (2 announcements)

MPS Pharmaa Limited reported a net loss of [amount context mismatch] crore for FY 2025-26, with no dividend recommended due to losses and no reserves created. The company faces operational suspension of its manufacturing plant and regulatory scrutiny over unvalued investments and stalled capital projects. Auditor reappointment was approved, but governance concerns persist around related party transactions and compliance with FDA renewal requirements.

MPS Pharmaa Limited announced that its FY2025-26 Annual Report is now available on its website via a dedicated web link and QR code, and shareholders must update PAN, KYC, and bank details to access it. The company also reminded physical shareholders of a SEBI-mandated special window for dematerialising shares purchased before April 1, 2019, open until February 4, 2027. Shareholders are urged to complete these updates promptly to maintain trading eligibility and grievance access.